Patients Health literacy for the intellectually disabled: is pharma d... What is health literacy and why is it important?
Patients Leveraging real-world data to meet payers’ needs Payers are becoming savvier in accepting real-world data.
Patients Time for change: PhRMA survey shows insurance creates barrie... Health insurance is not enough to provide the necessary affordable access to care for the US’ most vulnerable, finds new PhRMA report.
Patients Time for a new model in patient access Mig Sleeper, vice president, Global Pricing for Astellas Pharma Europe, explains why we must rethink how value is defined as we enter a new technological era for medicines.
Patients Time to take patient engagement to the next level Patient engagement in pharma is evolving, with some companies doing it better than others.
Patients UK-wide whole genome sequencing for newborns is feasible - b... Genomics England, the Department of Health and Social Care’s genome-sequencing hub, has this year ann
News Merck rare tumour drug Ezmekly backed for NHS use Merck's drug for tumours associated with rare disease neurofibromatosis type 1, Ezmekly, has been cleared for NHS use in children as young as two.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
